These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12634945)

  • 21. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
    Freeman SD; Jovanovic JV; Grimwade D
    Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of minimal residual disease in acute leukemia.
    van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
    J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
    Schüler F; Dölken G
    Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of minimal residual disease in acute myeloid leukemia.
    Buccisano F; Maurillo L; Spagnoli A; Del Principe MI; Ceresoli E; Lo Coco F; Arcese W; Amadori S; Venditti A
    Curr Opin Oncol; 2009 Nov; 21(6):582-8. PubMed ID: 19667983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of minimal residual disease by means of FISH and PCR methods and its clinical evaluation].
    Misawa S; Taniwaki M; Yokota S
    Rinsho Ketsueki; 1995 Apr; 36(4):293-8. PubMed ID: 7783332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
    Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
    Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
    Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
    Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
    [No Abstract]   [Full Text] [Related]  

  • 30. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
    Bacher U; Badbaran A; Fehse B; Zabelina T; Zander AR; Kröger N
    Exp Hematol; 2009 Jan; 37(1):135-42. PubMed ID: 19100523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.
    Taube T; Eckert C; Körner G; Henze G; Seeger K
    Leuk Res; 2004 Jul; 28(7):699-706. PubMed ID: 15158091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
    Bacher U; Zander AR; Haferlach T; Schnittger S; Fehse B; Kröger N
    Bone Marrow Transplant; 2008 Aug; 42(3):145-57. PubMed ID: 18587431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of multiparameter flow cytometry for disease monitoring in AML.
    Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia.
    Yoo SJ; Chi HS; Jang S; Seo EJ; Seo JJ; Lee JH; Park HS; Park CJ
    Haematologica; 2005 Nov; 90(11):1493-501. PubMed ID: 16266896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
    Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
    J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.